Drug
Apixaban clinical trials
Also written Eliquis, BMS-562247 and BMS-562247-01.
- studies test it
- 180
- open now
- 47
- in phase 3
- 58
- first study started
- 2004
Keep track of what changes. Save the apixaban studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
180 studies that test it; most in 2026 (21)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 10 |
| 2015 | 12 |
| 2016 | 17 |
| 2017 | 15 |
| 2018 | 10 |
| 2019 | 8 |
| 2020 | 11 |
| 2021 | 19 |
| 2022 | 7 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 10 |
| 2026 | 21 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 29
- Phase 2
- 34
- Phase 3
- 58
- Phase 4
- 48
- No phase
- 14
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 45 · Other 135
Bristol-Myers Squibb (25) · Pfizer (6) · Assistance Publique - Hôpitaux de Paris (5) · Ottawa Hospital Research Institute (5) · Northern Jiangsu People's Hospital (4) · Mayo Clinic (4) · Herlev and Gentofte Hospital (2) · Combined military hospital lahore (2)
Often tested with
Tested in the same studies.
Rivaroxaban (33) · Edoxaban (15) · Dabigatran (13) · Warfarin (11) · Enoxaparin (5) · Dalteparin (5) · Aspirin (4) · PRT064445 (3)
Studies
Open first, then newest update. How each study uses apixaban is read from its arms, and is right about nine times in ten.
Testing it · 180
- Oral Anticoagulation in Patients With Prior Deep Intracerebral Hemorrhage, Atrial Fibrillation, and Ischemic StrokeNot yet recruitingPhase 4Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07609654Written as Apixaban
- BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral AtherosclerosisRecruitingPhase 4Yonsei UniversityNCT07237308Written as Apixaban
- Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee ArthroplastyRecruitingNot applicableMilitary Hospital of TunisNCT07869615Written as Apixaban
- Vortosiran in Atrial FibrillationNot yet recruitingPhase 2Ribocure Pharmaceuticals ABNCT07870889Written as Apixaban
- Edoxaban Versus Apixaban in Cancer-Associated Venous ThromboembolismNot yet recruitingPhase 4Samsung Medical CenterNCT07852637Written as Apixaban
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial FibrillationRecruitingPhase 4Ottawa Hospital Research InstituteNCT04642430Written as Apixaban
- Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer TreatmentRecruitingPhase 3University of BirminghamNCT07160686Written as Apixaban
- Comparing the Safety and Efficacy of Apixaban and RivaroxabanRecruitingPhase 4VA Office of Research and DevelopmentNCT06953726Written as Apixaban
- Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple MyelomaRecruitingNot applicableCentre Hospitalier Universitaire de Saint EtienneNCT06474182Written as Apixaban
- The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery TrialRecruitingPhase 3Population Health Research InstituteNCT04284839Written as DOAC
- Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord InjuryRecruitingNot applicableLoewenstein HospitalNCT05484557Written as Apixaban
- SWITCH: Apixaban vs Vitamin K in HM3Not yet recruitingPhase 3Columbia UniversityNCT07471139Written as Apixaban
- Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2)Not yet recruitingPhase 3Unity Health TorontoNCT07779746Written as Eliquis
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver CirrhosisRecruitingPhase 1Insel Gruppe AG, University Hospital BernNCT04874428Written as Apixaban 2.5 mg Oral Tablet
- Apixaban to Prevent Decompensation of Early Liver Cirrhosis TrialNot yet recruitingPhase 3University College, LondonNCT07726693Written as Apixaban 2.5 mg twice daily
- Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism ProphylaxisNot yet recruitingNot applicableRon Beloosesky MDNCT07716332Written as Apixaban
- Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic DiseaseNot yet recruitingPhase 4James BayleyNCT07713875Written as Apixaban
- Apixaban Versus Warfarin for Left Ventricular ThrombusRecruitingPhase 3University of ArizonaNCT07709780Written as Apixaban
- Thromboprophylaxis in Lower Limb ImmobilisationRecruitingPhase 3Queen Mary University of LondonNCT06370273Written as Apixaban
- Stroke Prevention In Ischemic Stroke With Covert Atrial FibrillationRecruitingPhase 4Assistance Publique - Hôpitaux de ParisNCT06486792Written as Apixaban
See all 180 studies that test apixaban →
Given in every arm · 9 — apixaban is usual care beside what is tested
- A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy SubjectsCompletedPhase 1Lumosa Therapeutics Co., Ltd.NCT04809818Written as Apixaban
- Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCTCompletedPhase 2Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.NCT03288454Written as Apixaban
- Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older SubjectsCompletedPhase 1VarmX B.V.NCT05152420Written as Apixaban
- A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian SubjectsCompletedPhase 2Portola PharmaceuticalsNCT03310021Written as Apixaban
- Apixaban Versus Warfarin in Patients With Left Ventricular (LV) ThrombusCompletedPhase 3Hadassah Medical OrganizationNCT03232398Written as Apixaban Oral Tablet [Eliquis]
- Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary EmbolismTerminatedPhase 4Victor Tapson, MDNCT03988842Written as Apixaban
- Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02034591Written as Apixaban
- Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate KcentraCompletedPhase 1Thomas Jefferson UniversityNCT02270918Written as Apixaban
- A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02074358Written as Apixaban
As the comparator · 18 — what is tested is compared with apixaban
- Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersRecruitingPhase 3Regeneron PharmaceuticalsNCT07493304Written as Apixaban
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationRecruitingPhase 2Regeneron PharmaceuticalsNCT07175428Written as Apixaban
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationRecruitingPhase 3Regeneron PharmaceuticalsNCT07626411Written as Apixaban
- REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsRecruitingPhase 3Regeneron PharmaceuticalsNCT07015905Written as Apixaban
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus BacteremiaRecruitingPhase 4McGill University Health Centre/Research Institute of the McGill University Health CentreNCT06650501Written as Apixaban
- Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery DiseaseRecruitingPhase 4Samsung Medical CenterNCT07753200Written as Apixaban
- A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationActive, not recruitingPhase 3Janssen Research & Development, LLCNCT05757869Written as Apixaban
- A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTETerminatedPhase 3Anthos Therapeutics, Inc.NCT05171049Written as Apixaban
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical TherapyCompletedPhase 4Charite University, Berlin, GermanyNCT03463317Written as Apixaban
- A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult ParticipantsCompletedPhase 2Regeneron PharmaceuticalsNCT05618808Written as Apixiban
- Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy VolunteersCompletedPhase 2TAHO Pharmaceuticals Ltd.NCT06689436Written as 5 mg Apixaban Oral Tablet (US RS/RLD)
- A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for StrokeTerminatedPhase 3BayerNCT05643573Written as Apixaban
- Strategies for the Management of Atrial Fibrillation in patiEnts Receiving DialysisCompletedPhase 2Unity Health TorontoNCT03987711Written as Apixaban
- Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.CompletedPhase 2BayerNCT04218266Written as Apixaban
- Efficacy and Safety of MAA868 in Patients With Atrial FibrillationWithdrawnPhase 2Novartis PharmaceuticalsNCT03398434Written as Apixaban
- FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee ArthroplastyCompletedPhase 2BayerNCT03276143Written as Apixaban
- Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial FibrillationStatus unknownNot applicableYonsei UniversityNCT02633774Written as Apixaban
- Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)CompletedPhase 3Bristol-Myers SquibbNCT00423319Written as Apixaban
Codes
What other systems call apixaban · ClinicalTrials.gg INT005142
- MeSH (NLM) C522181apixabanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3Z9Y7UWC1JAPIXABANConfirmed FDA, NLM, Wikidata
- RxNorm 1364430Confirmed FDA, Wikidata
- Wikidata Q414462apixabanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61308ApixabanOne source FDA
- DrugBank DB06605One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C522181 | apixaban | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3Z9Y7UWC1J | APIXABAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1364430 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414462 | apixaban | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61308 | Apixaban | One source FDA |
| DrugBank | DB06605 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.